Waters is predicting strong sales growth for its Acquity UPLC system in 2006, driven by demand outside of its pharmaceutical base and expected enhancements to the system throughout the year.

The company finished a difficult year in which it issued two quarterly warnings that revenue would not meet previous guidance, but sales of its Acquity system surpassed expectations in the fourth quarter. The company also surprised the market by reporting a 9-percent increase in its fourth-quarter profit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.